MaxCyte, Inc. (MXCT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.28+1.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
MaxCyte aims to grow revenue to about $31 million in 2026. Revenue rose from $6.8M in 2025-Q3 to $9.7M in 2026-Q1. The company beat earnings estimates recently. A new CFO was hired to improve management.
MaxCyte is still losing money and faces Nasdaq delisting risk. Revenue growth may slow below 10%. The company cut staff and lost its chief commercial officer. These issues could hurt recovery.
The price is about 9% below our fair value near $1. Analysts expect about 10% revenue growth. Our view aligns with this cautious outlook.
Breaks if: Leadership instability or rising costs persist beyond 1 year
Breaks if: Closing bid price stays below $1 for 30 consecutive days
Full-year 2026 revenue falls below $30 million
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as MXCT operates in the healthcare sector, which has a favorable momentum. The current thesis is intact but faces challenges due to mixed recent performance and elevated risks.
The market seems to have a justified valuation with a low expectations gap, indicating that investors are not overly optimistic. MXCT is trading at a premium compared to its peers, suggesting that some growth potential is already reflected in its valuation.
Management is focused on achieving its revenue guidance of $30-32 million for 2026, although recent revenue has shown a decline. The company maintains a strong cash position, which is crucial for navigating potential risks in the near term.
The thesis hinges on management's ability to meet revenue targets and maintain cash levels, as well as external factors like the performance of sector bellwethers and overall economic conditions. Any cuts to guidance or worsening economic indicators could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on MXCT. However, there are concerns about achieving the 2026 revenue guidance of $30-32 million. The market backdrop has also shifted, with a recent decline affecting growth stocks.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Deliver full year 2026 total revenue between $30 million and $32 million, including core revenue of $25-27 million and SPL Program-related revenue of approximately $5 million.
Stated as a priority in 3 of last 3 quarters. Management reiterated full year 2026 revenue guidance of $30-32 million, including core revenue of $25-27 million and SPL Program-related revenue of about $5 million. Actual total revenue was $9.7 million in 2026-Q1 and $7.3 million in 2026-Q2, showing a decline quarter-over-quarter but consistent with guidance. The trajectory is mixed with revenue down in recent quarters but management maintains the full year target.
“Reiterates Full Year 2026 Guidance of $30-32 million total revenue”
“Reiterates 2026 revenue guidance of $30-32 million; core revenue $25-27 million”
“Full year revenue expected to be $30 million to $32 million”
In the next 1 to 3 years, MXCT's performance will depend on its execution against management priorities and the broader healthcare sector's health. Not investment advice.